Update of bioeconomy strategy unsureUncertainty regarding the amount of future funding and political support from the European Commission for the bioeconomy is set to hamper investments into the switch from oil-based industry production … more ➔
Serialisation: Time is running outDrug makers have only until two years from now to make their drugs and packaging counterfeit-resistant. By 9 February, 2019, every prescription drug pack must carry a 2D data matrix code that can be … more ➔
Biomanufacturing: The smell of successUntil recently, aroma compounds were either sourced directly from plants or made from petrochemicals with the help of chemical synthesis processes. Now a handful of biotechnological production approaches … more ➔
Preventing congestion in acute heart failu...German Adrenomed AG has decided to start clinical Phase II tests of the very first personalised treatment for the six million patients with acute congestive heart failure. Large trials suggest that the … more ➔
Longevity: Healthy ageingItalian, Swedish, and German researchers have started recruitment for a systematic investigation into the factors affecting longevity. more ➔
Blood cancer: Boosting chemotherapy effect...German and Swedish researchers have presented a strategy to predict and improve chemotherapy outcomes in patients with acute myelogenous leukaemia (AML). Currently, the five-year overall survival rate … more ➔
Phenotyping: The hidden mugshot in a culpr...Police investigators today begin searches for perpetrators with conventional DNA profiling – comparing a genetic signature from sperm or hair left at a crime scene with a database of identified offenders. … more ➔
Industry criticises EPO plansEuropean life sciences industry associations have voiced concerns over the latest addition to the European Patent Offices ambitious Early Certainty Initiative. While cutting the time for determining … more ➔
Microfluidics: Mapping DNA-bindersScientists at EPFL in Lausanne have developed a semi-automated technology that may be a game-changer by making the characterisation of the 2,000 DNA-binding proteins much faster, more accurate, and … more ➔
Next Big Thing in insurance: Digitalising...To date, insurance business models have always been based on damage control, but that paradigm is changing. Some insurers are now trying to hedge bets by motivating customers to get healthier and track … more ➔
